Video

Antibody-Drug Conjugates in Ovarian Cancer Treatment

Author(s):

Bradley J. Monk, MD, FACS, FACOG,Robert L. Coleman, MD, FACOG, FACS

Dr Michael Birrer highlights updated data on antibody-drug conjugates in ovarian cancer treatment.

Related Videos
4 experts are featured in this series.
Related Content
Ovarian Cancer | © Sebastian Kaulitzki - stock.adobe.com
January 17th 2025

Senaparib Receives NMPA Approval As First-Line Maintenance in Ovarian Cancer

Vadim Gushchin, MD; Teresa Diaz-Montes, MD, MPH, FACOG
April 20th 2023

Gushchin and Diaz-Montes Describe QOL Outcomes After Cytoreduction and HIPEC in Ovarian Cancer

Ovarian Cancer
December 20th 2024

Addition of Dostarlimab to Chemo and Niraparib Maintenance Boosts PFS in Advanced Ovarian Cancer

Monk Recaps Benefit of Rucaparib Maintenance Therapy in Advanced Ovarian Cancer
July 18th 2022

Monk Recaps Benefit of Rucaparib Maintenance Therapy in Advanced Ovarian Cancer

IMNN-01 Plus Perioperative Chemotherapy Maintains OS Benefit in Newly Diagnosed Advanced Ovarian Cancer
December 10th 2024

IMNN-001 Plus Perioperative Chemotherapy Maintains OS Benefit in Newly Diagnosed Advanced Ovarian Cancer

Ovarian Cancer_Dr Microbe - stock.adobe.com
December 10th 2024

Luveltamab Tazevibulin Produces Responses in Platinum-Resistant Ovarian Cancer